|
"liu c j"的相关文件
显示项目 901-910 / 1268 (共127页)
<< < 86 87 88 89 90 91 92 93 94 95 > >>
每页显示[10|25|50]项目
| 國立成功大學 |
2021 |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen, Chen C.-Y.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Lo, C.-C.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Drug resistance profile and clinical features for hepatitis C patients experiencing DAA failure in Taiwan
|
Hong, C.-M.;Lin, Y.-Y.;Liu, C.-J.;Lai, Y.-Y.;Yeh, S.-H.;Yang, H.-C.;Kao, J.-H.;Hsu, S.-J.;Huang, Y.-H.;Yang, S.-S.;Kuo, H.-T.;Cheng, P.-N.;Yu, M.-L.;Chen, P.-J. |
| 國立成功大學 |
2021 |
Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
|
Cheng, P.-N.;Chen, Chen C.-Y.;Yu, M.-L.;Lin, C.-C.;Lin, C.-Y.;Peng, C.-Y.;Tseng, K.-C.;Lo, C.-C.;Tseng, I.-H.;Liu, C.-J. |
| 國立成功大學 |
2021 |
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)
|
Hsu, W.-F.;Tsai, P.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Lai, H.-C.;Kuo, H.-T.;Hung, C.-H.;Tung, S.-Y.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Lin, C.-Y.;Yang, C.-C.;Lo, G.-H.;Tai, C.-M.;Lin, C.-W.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Yan, S.-L.;Bair, M.-J.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Lo, C.-C.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Huang, J.-F.;Dai, C.-Y.;Chuang, W.-L.;Yu, M.-L.;Peng, C.-Y. |
| 臺大學術典藏 |
2020-12-30T02:45:35Z |
Risk factors for ICU mortality in critically ill patients
|
SHAN-CHWEN CHANG; Jiang D.D.-S.; Yang P.-C.; Liu C.-J.; Lin S.-F.; Chen Y.-C.; Chen Y.-C.;Lin S.-F.;Liu C.-J.;Jiang D.D.-S.;Yang P.-C.;Shan-Chwen Chang |
| 臺大學術典藏 |
2020-12-30T02:43:38Z |
Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: In comparison with ceftazidime treatment
|
Hung C.-C.; Hsieh S.-M.; Sheng W.-H.; Liu C.-J.; Hsueh P.-R.; Fang C.-T.; SHAN-CHWEN CHANG; Chen Y.-C. |
| 臺大學術典藏 |
2020-12-30T02:43:05Z |
Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy
|
Chen P.-J.; SHAN-CHWEN CHANG; Kao J.-H.; Chang S.-Y.; Liu C.-J.; Chen M.-Y.; Hsieh S.-M.; Hung C.-C.; Sheng W.-H. |
| 臺大學術典藏 |
2020-12-30T02:43:03Z |
Safety and efficacy of cefpirome in comparison with ceftazidime in chinese patients with sepsis due to bacterial infections
|
Fang C.-T.;Chen Y.-C.;Lin S.-F.;Shau W.-Y.;Liu C.-J.;Sheng W.-H.;Wang J.-T.;Shan-Chwen Chang; Fang C.-T.; Chen Y.-C.; Lin S.-F.; Shau W.-Y.; Liu C.-J.; Sheng W.-H.; Wang J.-T.; SHAN-CHWEN CHANG |
| 臺大學術典藏 |
2020-12-29T06:37:47Z |
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
|
Su T.-H.; Liu C.-J.; Lo Y.-C.; SZU-MIN HSIEH; Sheng W.-H.; Sun H.-Y.; Liu C.-H.; Yang H.-C.; Liu W.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2020-12-29T06:37:44Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
|
Hung C.-C.; SZU-MIN HSIEH; Liu C.-J.; Liu C.-H.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
显示项目 901-910 / 1268 (共127页)
<< < 86 87 88 89 90 91 92 93 94 95 > >>
每页显示[10|25|50]项目
|
